Filing Flows › NRX Pharmaceuticals (NRXP) › R&D spending
NRX Pharmaceuticals (NRXP) R&D spending by quarter
NRX Pharmaceuticals' R&D spending was $2.1M in Q2 2026 (second quarter 2026), +62% from Q1 2026. Over the last 3 quarters it ranged from $558K (Q4 2025) to $2.1M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $2.1M | +62% | — |
| Q1 2026 | $1.3M | +135% | — |
| Q4 2025 | $558K | — | — |
Q2 2026 at a glance
NRX Pharmaceuticals, Q2 2026: revenue $1.1M, operating margin -590.8%, net loss $16.5M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is NRX Pharmaceuticals' R&D spending?
NRX Pharmaceuticals' R&D spending was $2.1M in Q2 2026 (second quarter 2026), +62% from Q1 2026.
How has NRX Pharmaceuticals' R&D spending changed?
Over the last 3 quarters it ranged from $558K (Q4 2025) to $2.1M (Q2 2026).